Protection conferred by a vaccine derived from an inactivated Egyptian variant of infectious bronchitis virus: a challenge experiment
- 42 Downloads
The current study investigated the protective efficacy of a formalin-inactivated infectious bronchitis virus (IBV) vaccine derived from the field strain KP729422, which exhibits low S1 spike protein sequence homology (77.1–79.8%) with the currently used vaccine strains in Egypt. Two-week-old, specific-pathogen-free chickens were subcutaneously inoculated with a single dose of the vaccine containing 106.7 50% embryo infective dose (EID50) of the inactivated virus. At 6 weeks of age, the chickens were challenged with 104 EID50 of the same virus strain via the oculonasal route. In comparison with the unvaccinated challenged group, the vaccinated chickens had significantly higher IBV-neutralizing antibody titers and exhibited efficient protection against challenge on the basis of tracheal ciliary activity. However, the challenge virus was recovered from the kidneys and tracheas of these chickens at rates of 40% and 60%, respectively. These findings suggest that a single application of the vaccine may provide sufficient clinical and respiratory protection, but may not ensure complete protection against infection by the challenge virus.
KeywordsInfectious bronchitis virus Variant Inactivated vaccine Protection
Compliance with ethical standards
Conflict of interest
The author declares that there are no conflicts of interest.
The experimental procedures were performed in accordance with the ethical standards applied in Veterinary Serum and Vaccine Research Institute, Abbassia, Egypt.
- Cavanagh, D., Davis, P.J., Darbyshire, J.H. and Peters, R.W., 1986. Coronavirus IBV: virus retaining spike glycopolypeptide S2 but not S1 is unable to induce virus-neutralizing or haemagglutination-inhibiting antibody, or induce chicken tracheal protection. Journal of General Virology, 67, 1435–1442CrossRefGoogle Scholar
- Cook, J.K., Orbell, S.J., Woods, M.A. and Huggins, M.B., 1999. Breadth of protection of the respiratory tract provided by different live-attenuated infectious bronchitis vaccines against challenge with infectious bronchitis viruses of heterologous serotypes. Avian Pathology, 28, 477–485CrossRefGoogle Scholar
- Liu, S., Zhang, X., Wang, Y., Li, C., Liu, Q., Han, Z., Zhang, Q., Kong, X. and Tong, G., 2009. Evaluation of the protection conferred by commercial vaccines and attenuated heterologous isolates in China against the CK/CH/LDL/97I strain of infectious bronchitis coronavirus. The Veterinary Journal, 179, 130–136CrossRefGoogle Scholar
- Magouz, A., Abdo, W., Abdelsabour, A., Elbestawy, A. and Desouky, A., 2018. Molecular and Histopathological Investigation of Avian Infectious Bronchitis Virus in the Delta of Egypt between 2016 and 2017. Pakistan Veterinary Journal, 38Google Scholar
- Raggi, L.G. and Lee, G.G., 1965. Lack of correlation between infectivity, serologic response and challenge results in immunization with an avian infectious bronchitis vaccine. The Journal of Immunology, 94, 538–543Google Scholar
- Sasipreeyajan, J., Pohuang, T. and Sirikobkul, N., 2012. Efficacy of different vaccination programs against Thai QX-like infectious bronchitis virus. The Thai Journal of Veterinary Medicine, 42, 73–79Google Scholar